Vertex Pharmaceuticals Incorpor Price Today
Vertex Pharmaceuticals Incorpor
VRTX
Healthcare
$104.47B
💰
Market Cap
29.1
💸
Price to Earnings
$13.9
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
16 |
Strong Buy |
10 |
Hold |
10 |
Sell |
1 |
Strong Sell |
1 |
VRTX Price Forecast Target
404.2 👉 574.0 +42%
VRTX EPS Forecast
13.9 👉 18.4 +32%
Financials
Profit Margin
37 %
Revenue Growth
9.3 %
Dividend
$ 0
Held Percent
0.1% - Insiders
95.7% - Institutions
4.2% - Public
Major Fund Holders
-
💰 $
-
💰 $
-
💰 $
-
💰 $
-
💰 $
Stock Ideas
Ron Baron Portfolio
Ron Baron is an American billionaire investor, entrepreneur, and the founder of Baron Capital Group, a well-known investment management firm. He is recognized for his long-term, growth-oriented investment approach and has built a successful track re…
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…
Ken Griffin Portfolio
Ken Griffin, the visionary founder of Citadel Investment Group, has transformed portfolio strategy with his innovative and tech-driven approach. Starting as a college student trading stock options, Griffin quickly rose to success and attracted signi…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …📮FAQ
Some Frequently Asked Questions.
The Vertex Pharmaceuticals Incorpor industry is Biotechnology
The Vertex Pharmaceuticals Incorpor sector is Healthcare
The Vertex Pharmaceuticals Incorpor forecasted predicted Price to Earnings PE ratio is 22.0
The Vertex Pharmaceuticals Incorpor Price to Earnings PE ratio is 29.1
The Market Capitalization of Vertex Pharmaceuticals Incorpor is $104.47B
There are total of 257563889 float shares with 95.7% held by Institutions and 0.1% held by insiders
The MVertex Pharmaceuticals Incorpor forecasted Earnings per Share EPS is $18.4
The Vertex Pharmaceuticals Incorpor Earnings per Share EPS is 13.9
The Vertex Pharmaceuticals Incorpor company has $0 gross profits with 37 profit margins
The Vertex Pharmaceuticals Incorpor Earnings Growth is 0.181% with 0.183% quarterly earnings growth
The Vertex Pharmaceuticals Incorpor Revenue is $9869200384 with 0.093 revenue growth
The price target for Vertex Pharmaceuticals Incorpor stock is $574.0 for the high target and $325.0 for the low target
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, with the following breakdown:
- Buy: 16
- Strong Buy: 10
- Hold: 10
- Sell: 1
- Strong Sell: 1
The Beta of Vertex Pharmaceuticals Incorpor is 0.4
The dividend of Vertex Pharmaceuticals Incorpor is $0
The dividend yield of Vertex Pharmaceuticals Incorpor is 0%
The biggest institutional and mutual fund holders of Vertex Pharmaceuticals Incorpor stock are
The Vertex Pharmaceuticals Incorpor ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0